UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 20, 2019 |
LEXARIA BIOSCIENCE CORP. |
(Exact name of registrant as specified in its charter) |
Nevada | | 000-52138 | | 20-2000871 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
100 – 740 McCurdy Road, Kelowna, BC Canada | | V1X 2P7 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code (250) 765-6424 |
N/A |
(Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 5.07 Submission of Matters to a Vote of Security Holders |
On June 20, 2019 at 1:00 p.m. (Pacific Time), Lexaria Bioscience Corp. (the “Company”) held its annual and special meeting of shareholders (the “Meeting”). There were 43,217,711 shares of the Company represented in person or by proxy at the meeting, constituting 55.1% of the Company’s issued share capital as at May 3, 2019, being the record date of the Meeting. The matters voted upon at the Meeting and the final voting results are set forth below:
Matter Being Voted On | For | Against | Abstain or Withheld | Broker Non-Vote | Percent Approved By |
To Elect Chris Bunka as a director | 19,320,620 | N/A | 235,561 | 23,661,530 | 98.8% |
To Elect John Docherty as a director | 19,292,585 | N/A | 263,596 | 23,661,530 | 98.65% |
To Elect Nicholas Baxter as a director | 19,320,092 | N/A | 236,089 | 23,661,530 | 98.79% |
To Elect Ted McKechnie as a director | 19,346,679 | N/A | 209,501 | 23,661,530 | 98.93% |
To Appoint Davidson & Company LLP as Auditors | 41,946,901 | N/A | 1,270,810 | 0 | 97.2% |
To Approve Executive Compensation | 19,101,153 | 455,028 | 0 | 23,661,530 | 97.67% |
To Approve Executive Compensation Annually | 692,428 | N/A | 181,412 | 23,661,530 | 3.54% |
To Approve Executive Compensation every two years | 345,768 | N/A | 181,412 | 23,661,530 | 1.77% |
To Approve Executive Compensation every three years | 18,641,658 | N/A | 181,412 | 23,661,530 | 95.32% |
To Approve the Equity Incentive Plan | 18,936,404 | 619,777 | 0 | 23,661,530 | 96.83% |
Based on the voting results for the preferred frequency of approving Executive Compensation, the Company will be seeking shareholder approval for executive compensation every three years. All of the proposals are described in detail in the Company’s proxy statement filed with the Securities Exchange Commission on May 22, 2019.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP. | |
| |
/s/ Chris Bunka | |
Chris Bunka | |
CEO, Principal Executive Officer | |
| |
Date: June 21, 2019 | |
